NIMH Outreach Partner

The Outreach Partnership Program is a nationwide initiative of the National Institute of Mental Health's (NIMH) Office of Constituency Relations and Public Liaison(OCRPL).

The Outreach Partnership Program works to increase the public's access to science-based mental health information through partnerships with national and state nonprofit organizations. The Program has a particular emphasis on reaching historically underserved populations. The Program also strives to enhance opportunities for the public to benefit from participation in research. These
partnerships provide NIMH with the opportunity to engage community organizations in dialogue to better understand the needs, questions, and concerns of those intended to benefit from the research the Institute supports.

Objectives:  The Outreach Partnership Program is vital to NIMH's efforts to deliver science-based information to communities across the country. Specifically, the Program is designed to:

  • Foster more widespread understanding about mental disorders, the brain, and behavior, thereby helping to reduce myths and misperceptions that contribute to stigma and discrimination;
  • Help promote the acceptance and social inclusion of individuals affected by mental illness;
  • Increase awareness of the role of basic, translational, and clinical research in the understanding, prevention, and treatment of mental illnesses; and
  • Increase awareness about the opportunities to benefit from participation in mental health research.

MAMH has been the Massachusetts Outreach Partner for the National Institute for Mental Health's (NIMH) Outreach Partnership Program since 2001. 

MAMH distributes science based information on mental illnesses and can arrange to have these materials sent to you at no cost.  We also encourage participation in clinical trials conducted by or funded by NIMH or the Natioal Institute for Health (NIH).  Information on clinical trials can be found on these pages (at websites listed below), or if you prefer, you can call Tim O'Leary at 617-742-7452 or email him at timoleary@mamh.org

A listing of NIMH brochures as well as information about the NIMH and the Outreach Partnership Program can be found at http://www.nimh.nih.gov/index.shtml
 or you can call or email Tim at the number and address listed above.

NIMH Twitter Chats

NIMH’s first Twitter Chat in recognition of National Children’s Mental Health Awareness Day. was Friday, May 3 from 11 a.m. to noon EST, NIMH Program Officer Ben Vitiello, M.D, from the Child and Adolescent Treatment and Preventive Intervention Research Branch, Division of Services and Intervention Research, fielded questions regarding attention deficit hyperactivity disorder in children and teens. More details are available here: http://www.nimh.nih.gov/news/science-news/2013/nimh-twitter-chat-on-attention-deficit-hyperactivity-disorder.shtml

To follow and participate in the chat via Twitter, use the hashtag #NIMHchats. You must have a Twitter account to ask questions. However, if you don’t have a Twitter account and you want to simply follow the conversation, you can do so at tweetchat.com. Just put in “NIMHchats” in the top hashtag box. The full transcript of the Twitter chat will be archived on the NIMH website a week after the chat.

NIMH’s second Twitter Chat was May 8 about PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections).


Find Clinical Trials by State:

http://www.clinicaltrials.gov/ct2/results/map/click?term=Behaviors+and+Mental+Disorders%5BCONDITION-BROWSE-BRANCH%5D&recr=Open&fund=01&map.x=163&map.y=177

Nationwide Recruitment: Bipolar Disorder (Pediatric) Research Study
Does your Child have Bipolar Disorder?
How do the brain and the symptoms of bipolar disorder change as children grow up?

At the NIH Clinical Center in Bethesda, Maryland a research study is being conducted that describes, over time, the moods and behavior of children using specialized testing and brain imaging to learn about specific brain changes associated with bipolar disorder.

This study seeks children and adolescent bipolar participants, ages 6-17, who have bipolar disorder. Participants must be diagnosed with Bipolar Disorder, currently being treated by a physician, medically healthy, and not currently hospitalized, psychotic or suicidal.

All clinical evaluations, research procedures, and outpatient visits are free of cost. Both parent and child must agree to the child’s participation. Children and parents are compensated for participation. Travel and lodging expenses are paid by NIMH. Participants from across the country may be eligible to participate.

Non-Treatment Descriptive Study:  Research study participation involves 1-3 outpatient visits, and may involve a phone interview at 6 months and repeat face-to-face evaluations every one to two years until the child turns 25. Those eligible to participate must be ages 6-17, and be able to perform research & computer tasks, neuropsychological testing, and MRI brain imaging.
Call for more information: 301-496-8381, TTY: 1-866-411-1010
Email: bipolarkids@mail.nih.gov
http://patientinfo.nimh.nih.gov/BipolarDisorderPediatric.aspx

------------------------------------------------
Nationwide Recruitment: Schizophrenia (Pediatric) Research Study
Childhood Onset Psychotic Disorders
(Inpatient: 3 weeks & 4-6 months) This study investigates the causes and treatment of childhood psychotic disorders that start prior to age 12. Thorough evaluations are provided including genetic studies, and further participation in a drug treatment sub-study is optional. Currently recruiting ages 6-18. [89-M-0006] http://patientinfo.nimh.nih.gov/SchizophreniaPediatric.aspx

-----------------------------------------------------------------------------
National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services.
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD click here http://patientinfo.nimh.nih.gov.

GENETICS STUDY ON SCHIZOPHRENIA SEEKING ADULT PARTICIPANTS

The VA Boston Healthcare System is working on a genetics study related to schizophrenia. The study is designed to help determine the underlying genetic variables responsible for this debilitating disease. This information can then be used to help develop improved methods of symptom management and to hopefully one day find a cure.

They are currently seeking to identify families with a history of schizophrenia--at least 3 adults (still living) diagnosed with schizophrenia, schizoaffective, schizotypal, or bipolar disorder with psychotic features, spanning at least 2 generations.
For a descriptive flyer: Descriptive Flyer
For a posting flyer: Posting Flyer

The principal investigator for the study is Dr. Lynn DeLisi.
------------------------------------------
Nationwide Recruitment
Schizophrenia and Genetics
(Outpatient: 1-2 days) This study examines the role genes play in schizophrenia. Eligible participants have a diagnosis of schizophrenia and no serious drug or alcohol abuse. If possible, the siblings and/or parents of the individuals are invited for interviews and blood donation. Travel and lodging assistance may be available. Recruiting ages 18-55. [95-M-0150] http://patientinfo.nimh.nih.gov/SchizophreniaAdult.aspx#161

National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services. For more information on research conducted by the National Institute of Mental Health in Bethesda, MD click here http://patientinfo.nimh.nih.gov.
--------------------------------------------------
Nationwide Recruitment
Bipolar Disorder (Pediatric) Research Study
Treatment of Severe Mood Dysregulation, SMD
(Inpatient: 12- to 15 weeks) This study tests the efficacy of different treatments for decreasing irritability in children with severe mood and behavioral problems. Participants have symptoms of severe irritability and are not doing well on their current medications. The child must be currently in treatment with a physician, medically healthy and not currently hospitalized, psychotic, or suicidal. The study includes day or full hospitalization to discontinue medication, followed by either methylphenidate plus citalopram, or methylphenidate plus placebo. Recruiting ages 7-17. [09-M-0034] 
http://patientinfo.nimh.nih.gov/BipolarDisorderPediatric.aspx#221 
National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services.
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD click here http://patientinfo.nimh.nih.gov.
-------------------------------------------------------------------------------------
National Institutes of Health Clinical Trials website: http://www.clinicaltrials.gov/NIMH Clinical Trials webpage: http://www.nimh.nih.gov/trials

Nationwide Recruitment: 
Schizophrenia (Pediatric) Research Study
Childhood Onset Psychotic Disorders

(Inpatient: 3 weeks & 4-6 months) This study investigates the causes and treatment of childhood psychotic disorders that start prior to age 12. Thorough evaluations are provided including genetic studies, and further participation in a drug treatment sub-study is optional. Currently recruiting ages 6-18. [89-M-0006] http://patientinfo.nimh.nih.gov/SchizophreniaPediatric.aspx 
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD click here http://patientinfo.nimh.nih.gov.
-------------------------------------------------------------

Nationwide Recruitment: Bipolar Disorder (Pediatric) Research Study
Treatment of Severe Mood Dysregulation (SMD)
(Inpatient: 12 to 15 weeks)

This study tests the efficacy of different treatments for decreasing irritability in children with severe mood and behavioral problems. Participants have symptoms of severe irritability and are not doing well on their current medications. The child must be currently in treatment with a physician, medically healthy, and not currently hospitalized, psychotic or suicidal. The study includes day or full hospitalization to discontinue medication, followed by either methylphenidate plus citalopram, or methylphenidate plus placebo. Recruiting ages 7-17. [09-M-0034] http://patientinfo.nimh.nih.gov/BipolarDisorderPediatric.aspx

National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services.
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD click here http://patientinfo.nimh.nih.gov.

----------------------------------------------------------

Nationwide Recruitment
Bipolar Disorder (Pediatric) Research Study
*Descriptive Study of Bipolar Disorder (Outpatient: 1-3 visits and may include follow-up visits until age 25)

This study describes, over time, the moods and behavior of children. Participants must have a diagnosis of Bipolar Disorder, be currently in treatment with a physician, medically healthy and not currently hospitalized, psychotic or suicidal. The study includes performing research & computer tasks, neuropsychological testing, and MRI brain imaging. Recruiting ages 6-17. [00-M-0198]

To find out about study criteria and qualifications, or for more information, please call (301 496-8381) or email us at bipolarkids@mail.nih.govhttp://patientinfo.nimh.nih.gov/BipolarDisorderPediatric.aspx
for more information on research conducted by the National Institute of Mental Health in Bethesda, MD click here http://patientinfo.nimh.nih.gov.
-----------------------------------------------------------------------------
Nationwide Recruitment: Bipolar Disorder (Pediatric) Research Study
Treatment of Severe Mood Dysregulation, SMD (Inpatient: 12- to 15 weeks)

This study tests the efficacy of different treatments for decreasing irritability in children with severe mood and behavioral problems. Participants have symptoms of severe irritability and are not doing well on their current medications. The child must be currently in treatment with a physician, medically healthy and not currently hospitalized, psychotic or suicidal. The study includes day or full hospitalization to discontinue medication, followed by either methylphenidate plus citalopram, or methylphenidate plus placebo. Recruiting ages 7-17. [09-M-0034] National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services.
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD click here http://patientinfo.nimh.nih.gov/BipolarDisorderPediatric.aspx

---------------------------------------------------------------
Nationwide Recruitment: Bipolar Disorder (Adult) Research Study
Bipolar Disorder & Riluzole (Outpatient or Inpatient: 8 weeks)

This study of Riluzole (an FDA-approved drug for Lou Gehrig’s disease, ALS) tests how this drug affects glutamate in the brain and improves treatment-resistant depressive symptoms (failure to reduce symptoms after taking two or more antidepressants.) Recruiting ages 18-70. [03-M-0092]http://patientinfo.nimh.nih.gov/BipolarDisorderAdult.aspx

National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services.
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD

National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services.

For more information on research conducted by the National Institute of Mental Health in Bethesda, MD Download an NIMH Brochre:
Clinical Studies Q
--------------------------------------------------------------------------------------------

Clinical Trial Recruitment for Brain Functions in Children

Researchers at the National Institute of Mental Health are conducting studies to learn how the brain functions in children and adolescents with anxiety and/or depression. 

These studies seek boys and girls ages 8-17 to participate in research at the NIH Clinical Center in Bethesda, Maryland. Research participation includes brain imaging and computer-based problem solving and memory tasks. Treatment is available over 8 weeks of outpatient visits. Participation includes: Psychiatric diagnostic interviews, physical examination, and your choice of either cognitive-behavioral therapy or treatment medication. Participants must: Be between 8-17, otherwise medically healthy, and not taking any psychiatric medications. All clinical evaluations, research procedures, and outpatient visits are free of cost. Both parent and child must agree to the child’s participation. Transportation reimbursement available.
http://patientinfo.nimh.nih.gov/AnxietyDisordersPediatric.aspx
Protocol No. 01-M-0192
For more information:  Call: 301 - 402 - 8225 or email: kidswithworries@mail.nih.gov
TTY: 1-866-411-1010

---------------------------------------------------------

Nationwide Recruitment: Schizophrenia (Pediatric) Research Study
Childhood Onset Psychotic Disorders
(Inpatient: 3 weeks & 4-6 months) This study investigates the causes and treatment of childhood psychotic disorders that start prior to age 12. Thorough evaluations are provided including genetic studies, and further participation in a drug treatment sub-study is optional. Currently recruiting ages 6-18. [89-M-0006] http://patientinfo.nimh.nih.gov/SchizophreniaPediatric.aspx
National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services.

For more information on research conducted by the National Institute of Mental Health in Bethesda, MD click here http://patientinfo.nimh.nih.gov.

--------------------------------------------------------------------
Nationwide Recruitment: PANDAS (Pediatric) Research Study
Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) (Inpatient: 5-days and Outpatient: 1-2 days) This study investigates whether intravenous immunoglobulin (IVIG) improves the symptoms of PANDAS. Recruiting ages 4-12. [11-M-0058] http://patientinfo.nimh.nih.gov/Pandas.aspx

For more information about PANDAS: http://www.nimh.nih.gov/health/publications/pandas/pandas-frequently-asked-questions-about-pediatric-autoimmune-neuropsychiatric-disorders-associated-with-streptococcal-infections.shtml

------------------------------------------------------------------------

Nationwide Recruitment: Bipolar Disorder Pediatric Research Study

Clinical Trial of Citalopram and Methylphenidate in Severe Mood Dysregulation

This study is testing the effectiveness of methylphenidate plus citalopram versus. methylphenidate plus placebo for decreasing irritability in children with severe mood dysregulation (SMD). Children with SMD display chronic anger, sadness, or irritability, as well as hyperarousal (such as insomnia, distractibility, hyperactivity) and extreme responses to frustration (such as frequent, severe temper tantrums).

Children ages seven to 17 with SMD may be eligible to participate in this 12- to 15-week inpatient or outpatient study. This study has four phases. During Phase I participants are gradually withdrawn from all current psychotropic medications. Phase II is a one-week psychotropic medication-free period. During Phase III, which lasts two weeks, participants are treated with methylphenidate alone. Phase IV lasts for eight weeks. During this time, participants continue methylphenidate treatment and are randomly assigned to also receive either citalopram or placebo.

At the end of the study, those who received methylphenidate plus placebo will have the opportunity to receive methylphenidate plus active citalopram if clinically appropriate.

All procedures and medications associated with the research are provided at no cost to participants, and transportation expenses are reimbursed by NIMH. Schooling will be provided while on the inpatient unit or in day treatment.

To find out more information, please call (301) 496-8381 or email irritablekids@mail.nih.gov.
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD click here http://patientinfo.nimh.nih.gov.


NATIONWIDE RECRUITMENT: DEPRESSION ADULT RESEARCH STUDY
RAPID ANTIDEPRESSANT EFFECTS OF KETAMINE

Individuals who have been diagnosed with major depression may be able to participate in a trial designed to understand the causes of depression and rapid antidepressant response. Specifically, NIMH is testing whether ketamine, a drug that affects glutamate in the brain, will improve symptoms of depression within a matter of hours.

Individuals who are 18-65 years of age and have been diagnosed with major depression (unipolar) and previously failed to respond to treatment may be eligible for an inpatient study designed to bring about a rapid antidepressant effect.

After completion of the study the participant is transitioned back to a clinician in the community. All research participation is without cost and NIMH will cover all transportation costs from anywhere in the United States. Compensation is provided for study procedures.

For more information, please call 1-877-MIND-NIH (1-877-646-3644) or email moodresearch@mail.nih.gov.

For more information on research conducted by the NIMH in Bethesda, MD click here http://patientinfo.nimh.nih.gov.

MORE NIMH News:

TOP 10 RESEARCH ADVANCES FOR 2012
NIMH Director’s Blog, Top 10 Research Advances for 2012: http://www.nimh.nih.gov/about/director/index.shtml#p143773

The NIMH video highlighting research strategies of suicide prevention is now available:
http://www.nimh.nih.gov/news/media/video/nimh-director-talks-with-nimh-researcher-about-the-high-priority-research-strategies-of-suicide-prevention.shtml

National Strategy for Suicide Prevention
. If you missed the launch, you can view the archived webcast on the Surgeon General’s website: http://www.surgeongeneral.gov/library/reports/national-strategy-suicide-prevention/index.html

NIMH has released an update to its publication series on depression and co-occurring disorders. These publications are now available for ordering.  Simply send an email to Timoleary@mamh.org

·        ·         NIH 11-5002: Depression and Cancer

·        ·         NIH 11-5003: Depression and Diabetes

·        ·         NIH 11-5004: Depression and Heart Disease

·        ·         NIH 11-5005: Depression and HIV/AIDS

·        ·         NIH 11-5006: Depression and Stroke

·        ·         NIH 11-5007: Depression and Parkinson's Disease

·        ·         NIH 11-7743: Depression and Osteoporosis

·        ·         NIH 11-7744: Depression and Chronic Pain

Some booklets and fact sheets available from NIMH:

Psychotherapy: Describes different types of psychotherapy for children and adults
http://www.nimh.gov/health/topics/psychotherapies/

Looking at My Genes: What Do They Tell me?
http://www.nimh.gov/health/publications/looking-at-my-genes-what-can-they-tell-me/

 Post-Traumatic Stress Disorder Research Fact Sheet: A fact sheet with a brief description of post-traumatic stress disorder (PTSD) and treatment research.
http://www.nimh.gov/health/publications/post-traumatic-stress-disorder-research-fact-sheet/

 Borderline Personality Disorder: A brief overview that focuses on the symptoms, treatments, and research findings of borderline personality disorder.
http://www.nimh.gov/health/publications/borderline-personality-disorder-fact-sheet/

 Medications: A detailed booklet that describes the medications for treatment mental disorders including a comprehensive list of medications
http://www.nimh.gov/health/publications/medications/

 Men and Depression: A detailed booklet that describes what you need to know about depression in men; how it looks, how it feels, getting help, and getting better.
http://www.nimh.gov/health/publications/men-and-depression/

NIMH RESEARCH AND PRESENTATIONS AT 2011 OUTREACH PARTNERS ANNUAL MEETING.

The following papers, power point presentations, and summaries can be downloaded here.   

Early Identification and Intervention for Depression in the Preschool Period Joan Luby M.D., Washington University in St. Louis School of Medicine (34 slide Power Point) 

Preschool Depression: The Importance of Identification of Depression Early in Development.  Joan L. Luby, M.D. (5 page article)

Predictors and Mechanisma of Conversion to Psychosis in At-Risk Youth: Toward a Prevention Strategy  Tyrone D. Cannon Ph.D. UCLA  (33 slide presentation)
Overview of Presentation:  Cannon Overview

Preventing Depression in At-Risk Adolescents Paul Rohde, Ph.D. Oregon Research Institute (34 slide presentation)

Effects of Bullying and Early Abuse on Brain Development and Mental Health  Martin H. Teicher, M.D., Ph.D., Department of Psychiatry, Harvard Medical School, Developmental Biopsychiatry Research Program McLean Hospital  (85 Slide Presentation)

 
There are two new science education resources now available on the NIMH website:

Brain Basics—an animated video describing how the brain works
http://www.nimh.nih.gov/health/brain-basics/brain-basics.shtml

Neuroscience and Psychiatry—an online training tool designed to introduce neuroscience concepts to psychiatry residents
http://www.nimh.nih.gov/health/neuroscience-and-psychiatry/neuroscience-and-psychiatry-module-1-br-translating-neural-circuits-into-novel-therapeutics.shtml

SAMHSA has released two new fact sheets to support National Children’s Mental Health Awareness Day activities:
· Childhood Trauma's Impact on Health Risks: http://www.samhsa.gov/children/social_media_apr2011.asp
· Building Resilience in Children and Youth Dealing with Trauma: http://www.samhsa.gov/children/trauma_resilience.asp

There are two featured stories on mental illnesses in the latest issue of the National Library of Medicine’s magazine:
1) Phobias and Anxiety Disorders: Basic information about anxiety disorders including symptoms and treatments
2) Clinical Trials: Definitions of clinical trials and personal stories of individuals who have participated in NIH studies
http://www.nlm.nih.gov/medlineplus/magazine/issues/fall10/toc.html.

New NIMH Research Findings:

NIMH and colleagues reported on data analyzed from the National Comorbidity Study-Adolescent Supplement (NCS-A), a nationally representative, face-to-face survey of more than 10,000 teens ages 13 to 18. Overall, nearly half of the sample reported having met diagnostic criteria for at least one disorder over a lifetime, and about 20 percent reported that they suffered from a mental disorder with symptoms severe enough to impair their daily lives. Check out the Science Update:

http://www.nimh.nih.gov/science-news/2010/national-survey-confirms-that-youth-are-disproportionately-affected-by-mental-disorders.shtml

United Way